Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
PaperCitations, authors & open-access status
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 256 citations, 2021 year and bronze oa status.
256
Citations
2021
Year
bronze
OA Status